Merida Biosciences is a biotechnology company pioneering a new class of precision therapeutics designed to selectively and durably eliminate pathogenic antibodies that drive disease. The company is advancing a robust pipeline to precisely eliminate the root cause of multiple autoimmune and allergic conditions that are inadequately treated today. Its lead program is designed to specifically and rapidly clear the pathogenic autoantibodies that cause Graves' disease, an autoimmune disorder that affects the thyroid gland. Merida was publicly launched in April 2025 and is based in Cambridge, MA. For more information about Merida, visit www.meridabio.com.
Company Details
- Employees
- 45
- Founded
- -
- Address
- 500 Technology Sq, Cambridge,massachusetts 02139,united States
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.meridabio.com
- HQ
- Cambridge, Massachusetts
Merida Biosciences Questions
Merida Biosciences's website is https://www.meridabio.com
Merida Biosciences's LinkedIn profile is https://www.linkedin.com/company/merida-biosciences
Merida Biosciences has
45 employees.
View email and phone details for 45
employees at Merida Biosciences.
Merida Biosciences's industry is
Biotechnology Research
Merida Biosciences's top competitors are
Cugene Inc.,
Aviceda Therapeutics,
Pledge Therapeutics,
Compass Therapeutics Inc.,
Nona Biosciences,
Portal,
1910 Genetics,
Marengo Therapeutics,
Incendia Therapeutics,
Qld Biotherapeutics Inc.
Merida Biosciences's categories are Biotechnology Research
Merida Biosciences's founding year is 2022
